Overcoming functional impairment in postpartum depressed or anxious women: a pilot trial of desvenlafaxine with flexible dosing

Therapeutic Advances in Psychopharmacology

Volumn 6, Issue 4, 2016, Pages 269-276

  Misri, Shaila ^a   Swift, Elena ^b,c   Abizadeh, Jasmin ^b,c   Shankar, Radhika ^b,c  

^a CHILDREN S AND WOMEN S HEALTH CENTRE OF BRITISH COLUMBIA   (Canada)

^b Oak Tree Clinic   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

antidepressants; anxiety; desvenlafaxine; functional restoration; mental health; postpartum depression

Indexed keywords

DESVENLAFAXINE;

ADULT; ANXIETY DISORDER; ARTICLE; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; DECREASED APPETITE; DIARRHEA; DIZZINESS; DROWSINESS; DRUG TOLERABILITY; FAMILY LIFE; FATIGUE; FEMALE; FUNCTIONAL ASSESSMENT; HEADACHE; HEARTBURN; HOT FLUSH; HUMAN; INSOMNIA; INTENTION TO TREAT ANALYSIS; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MOOD DISORDER; MUSCLE TONE; NAUSEA; NEUROPSYCHOLOGICAL TEST; OPEN STUDY; PENN STATE WORRY QUESTIONNAIRE; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PUERPERAL DEPRESSION; REMISSION; SHEEHAN DISABILITY SCALE; SOCIAL BEHAVIOR; SWEAT GLAND DISEASE; TERTIARY CARE CENTER; TREATMENT DURATION; TREATMENT RESPONSE; XEROSTOMIA;

EID: 85016322228     PISSN: 20451253     EISSN: 20451261     Source Type: Journal    
DOI: 10.1177/2045125316656297     Document Type: Article

References (34)

1. L.ApplebyR.WarnerA.WhittonB.Faragher (1997) A controlled study of fluoxetine and cognitive-behavioural counselling in the treatment of postnatal depression. BMJ314: 932–936.
2. A.ClaytonS.KornsteinB.DunlopK.FochtJ.MusqnungT.Ramey. (2013) Efficacy and safety of desvenlafaxine 50 mg/d in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder. J Clin Psychiatry74: 1010–1017.
3. L.CohenA.VigueraS.BouffardR.NonacsC.MorabitoM.Collins. (2001) Venlafaxine in the treatment of postpartum depression. J Clin Psychiatry62: 592–596.
4. T.Di ScaleaK.Wisner (2009) Pharmacotherapy of postpartum depression. Expert Opin Pharmacother10: 2593–2607.
5. B.DunlopS.ReddyL.YangS.LubaczewskiK.FochtC.Guico-Pabia (2011) Symptomatic and functional improvement in employed depressed patients: a double-blind clinical trial of desvenlafaxine versus placebo. J Clin Psychopharmacol31: 569–576.
6. J.EmmanuelS.SimmondsP.Tyrer (1998) Systematic review of the outcome of anxiety and depressive disorders. Br J Psychiatry Suppl34: 35–41.
7. M.FavaA.RushJ.AlpertG.BalasubramaniS.WisniewskiC.Carmin. (2008) Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR* D report. Am J Psychiatry3: 342–351.
8. L.Ginsberg (2009) Impact of drug tolerability on the selection of antidepressant treatment in patients with major depressive disorder. CNS Spectr14: 8–14.
9. S.GrigoriadisD.de Camps MeschinoE.BarronsL.BradleyA.EadyA.Fishell. (2011) Mood and anxiety disorders in a sample of Canadian perinatal women referred for psychiatric care. Arch Womens Ment Health14: 325–333.
10. M.Hamilton (1959) The assessment of anxiety states by rating. Br J Med Psychol32: 50–55.
11. M.Hamilton (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry23: 56.
12. D.KimC.EppersonA.WeissK.Wisner (2014) Pharmacotherapy of postpartum depression: an update. Expert Opin Pharmacother15: 1223–1234.
13. S.KornsteinC.Guico-PabiaR.Fayyad (2014a) The effect of desvenlafaxine 50 mg/day on a subpopulation of anxious/depressed patients: a pooled analysis of seven randomized, placebo-controlled studies. Hum Psychopharmacol29: 492–501.
14. S.KornsteinR.McIntyreM.ThaseM.Boucher (2014b) Desvenlafaxine for the treatment of major depressive disorder. Expert Opin Pharmacother15: 1449–1463.
15. R.LamS.KennedyS.GrigoriadisR.McIntyreR.MileyR.Ramasubbu. (2009) Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults: III. Pharmacotherapy. J Affect Disord117: S26-S43.
16. M.LiebowitzK.TourianE.HwangL.Mele (2013) A double-blind, randomized, placebo-controlled study assessing the efficacy and tolerability of desvenlafaxine 10 and 50 mg/day in adult outpatients with major depressive disorder. BMC Psychiatry13: 94.
17. R.McIntyreR.FayyadC.Guico-PabiaM.Boucher (2015) A post hoc analysis of the effect of weight on efficacy in depressed patients treated with desvenlafaxine 50 mg/d and 100 mg/d. Prim Care Companion CNS Disord17.
18. T.MeyerM.MillerR.MetzgerT.Borkovec (1990) Development and validation of the Penn State Worry Questionnaire. Behav Res Ther28: 487–495.
19. S.MisriJ.AbizadehG.AlbertD.CarterD.Ryan (2012) Restoration of functionality in postpartum depressed mothers: an open-label study with escitalopram. J Clin Psychopharmacol32: 729–732.
20. S.MisriJ.AbizadehS.SandersE.Swift (2015) Perinatal generalized anxiety disorder: assessment and treatment. J Womens Health24: 762–770.
21. S.MontgomeryM.Åsberg (1979) A new depression scale designed to be sensitive to change. Br J Psychiatry134: 382–389.
22. R.NonacsC.SoaresA.VigueraK.PearsonJ.PoitrasL.Cohen (2005) Bupropion SR for the treatment of postpartum depression: a pilot study. Int J Neuropsychopharmcol8: 445–449.
23. T.PearlsteinM.HowardA.SalisburyC.Zlotnick (2009) Postpartum depression. Am J Obstet Gynecol200: 357–364.
24. Pfizer Canada Inc. (2014) PRISTIQ® Desvenlafaxine Extended-Release Tablets (50 and 100 mg Desvenlafaxine as Desvenlafaxine Succinate). Report of Product Monograph. Available at: http://www.pfizer.ca/sites/g/files/g10017036/f/201505/Pristiq_DC_PM_E_170902_3Dec2014.pdf. (accessed 10 June 2015).
25. D.V.Sheehan (1983) The Anxiety Disease. New York: Scribner.
26. D.SheehanY.LecrubierK.SheehanP.AmorimJ.JanavsE.Weiller. (1998) The Mini-International Neuropsychiatric Interview (M.I.N.I): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry59: 22–33.
27. K.SheehanD.Sheehan (2008) Assessing treatment effects in clinical trials with the discan metric of the Sheehan Disability Scale. Int Clin Psychopharmacol23: 70–83.
28. A.SteinR.PearsonS.GoodmanE.RapaA.RahmanM.McCallum. (2014) Effects of perinatal mental disorders on the fetus and child. Lancet384: 1800–1819.
29. Z.StoweJ.CasarellaJ.LandryC.Nemeroff (1995) Sertraline in the treatment of women with postpartum major depression. Depression3: 49–55.
30. M.ThaseS.KornsteinJ.GermainQ.JiangC.Guico-PabiaP.Ninan (2009) An integrated analysis of the efficacy of desvenlafaxine compared with placebo in patients with major depressive disorder. CNS Spectr14: 144–154.
31. K.TourianQ.JiangP.Ninan (2010a) Analysis of the effect of desvenlafaxine on anxiety symptoms associated with major depressive disorder: pooled data from 9 short-term, double-blind, placebo-controlled trials. CNS Spectr15: 187–193.
32. K.A.TourianC.LeurentJ.GraepelP.T.Ninan (2010b) Desvenlafaxine and weight change in major depressive disorder. Prim Care Companion J Clin Psychiatry12.
33. D.WardenM.TrivediS.WisniewskiI.LesserJ.MitchellG.Balasubramani. (2009) Identifying risk for attrition during treatment for depression. Psychother Psychosom78: 372–379.
34. K.YonkersH.LinH.HowellA.HeathL.Cohen (2008) Pharmacologic treatment of postpartum women with new-onset major depressive disorder: a randomized controlled trial with paroxetine. J Clin Psychiatry69: 659–665.